Immunization is widely regarded as one of the most effective and beneficial tools for protecting the public's health. In the United States, immunization programs have resulted in the eradication of smallpox, the elimination of polio, and the control and near elimination of once-common, often debilitating and potentially life-threatening diseases, including measles, mumps, rubella, diphtheria, pertussis, tetanus, and Haemophilus influenza type b. Along with the benefits of widespread immunization, however, have come concerns about the safety of vaccines. No vaccine is perfectly safe or effective, and vaccines may lead to serious adverse effects in some instances. Furthermore, if a serious illness is observed after vaccination, it is often unclear whether that sequence is coincidental or causal, and it can be difficult to determine the true nature of the relationship, if any, between the vaccination and the illness. Ironically, the successes of vaccine coverage in the United States have made it more difficult for the public to weigh the benefits and complications of vaccines because the now-controlled diseases and their often-serious risks are no longer familiar.However, because vaccines are so widely used-and because state laws require that children be vaccinated before entering daycare and school, in part to protect others-it is essential that safety concerns be fully and carefully studied. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism, the first of a series from the Institute of Medicine (IOM) Immunization Safety Review Committee, presents an assessment of the evidence regarding a hypothesized causal association between the measles-mumps-rubella (MMR) vaccine and autism, an assessment of the broader significance for society of the issues surrounding the MMR-autism hypothesis, and the committee's conclusions and recommendations based on those assessments.
Kathleen Stratton, Alicia Gable, Padma Shetty, and Marie McCormick, Editors, Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention
1 Front Matter; 2 Executive Summary; 3 Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism; 4 Appendix A: Januaray 11, 2001 - Meeting Agenda; 5 Appendix B: March 8, 2001 - Meeting Agenda; 6 Appendix C: Immunization Safety Review Committee Biosketches; 7 Appendix D: Research Needs and Opportunities Related to the Measles-Mumps-Rubella Vaccine and Autism
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee to Study Priorities for Vaccine Development, Robert S. Lawrence, Jane S. Durch, Kathleen R. Stratton
Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on the Elimination of Tuberculosis in the United States, Lawrence Geiter
Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Care Services, Committee on Immunization Finance Policies and Practices
Institute of Medicine, Board on Health Promotion and Disease Prevention, Committee on the Review of the National Immunization Program's Research Procedures and Data Sharing Program
Institute of Medicine, Medical Follow-Up Agency, Committee on U.S. Military Malaria Vaccine Research: A Program Review, Myron M. Levine, Patricia M. Graves
Institute of Medicine, Committee to Review the Adverse Consequences of Pertussis and RubellaVaccines, Harvey V. Fineberg, Cynthia J. Howe, Christopher P. Howson
Institute of Medicine, Board on Population Health and Public Health Practice, Committee on the Prevention and Control of Viral Hepatitis Infections, Abigail E. Mitchell, Heather M. Colvin
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Theresa M. Wizemann, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Board on Population Health and Public Health Practice, Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule
Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Phase II Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Rino Rappuoli, Dennis Fryback, Charles Phelps, Kinpritma Sangha, Guruprasad Madhavan
National Academy of Engineering, Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Phase III Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Rino Rappuoli, Charles Phelps, Guruprasad Madhavan
Institute of Medicine, Board on Population Health and Public Health Practice, Committee to Review Adverse Effects of Vaccines, Ellen Wright Clayton, Erin Rusch, Andrew Ford, Kathleen Stratton
Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Care Services, Committee on Immunization Finance Policies and Practices